Physician profile

Bruce Edwin Vannatta

Interventional Cardiology · Los Alamitos, CA

NPI 1629074877

$9,492.10

in general payments reported to CMS, 2019-2025

40 companies · $801 in 2025

The $801 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

See the full distribution for Interventional Cardiology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,865.05

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $1,937.45 2019-2025
Boehringer Ingelheim Pharmaceuticals, INC. $1,248.94 2019-2025 Jardiance
Novo Nordisk INC $994.76 2021-2025 Ozempic, Wegovy
Sanofi-Aventis U.S. LLC $682.07 2019-2023
Edwards Lifesciences Corporation $507.52 2019
Astrazeneca Pharmaceuticals LP $496.37 2019-2024 Farxiga, Brilinta, Wainua
Amgen INC. $485.09 2019-2025 Repatha, Repatha
Regeneron Healthcare Solutions, INC. $466.10 2019-2025 Evkeeza, Praluent
Abiomed $376.64 2019-2025 Impella
Janssen Pharmaceuticals, INC $220.57 2019-2022
Atricure, INC. $215.61 2021-2025 Atriclip Laa Exclusion System
Pfizer INC. $211.10 2022-2025
Abbott Laboratories $201.30 2021-2023 Mitraclip
Abbvie INC. $181.26 2023-2025 Natrelle Saline-Filled Breast Implants
Merck Sharp & Dohme LLC $180.05 2022-2025 Verquvo
Show all 40 companies
CompanyGeneral paymentsYearsTop products
E.R. Squibb & Sons, L.L.C. $136.86 2021-2023 Camzyos, Eliquis
Merz North America, INC. $108.47 2019
Allergan, INC. $89.78 2019-2022
Esperion Therapeutics, INC. $83.42 2020-2022
Davol INC. $61.64 2022
Astellas Pharma US INC $58.82 2021
Actelion Pharmaceuticals US, INC. $57.61 2019-2020
Boston Scientific Corporation $50.83 2019-2022
Amarin Pharma, INC. $44.42 2019-2021
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $42.03 2024-2025 Lifevest
Becton, Dickinson and Company $40.55 2024 Bard Urinary Drainage Bag
United Therapeutics Corporation $40.38 2019
Recor Medical INC $39.25 2025 Paradise Ultrasound Renal Denervation System
Biotronik INC. $29.67 2021-2022
Gilead Sciences, INC. $28.31 2019
Tepha INC $27.50 2020
Bayer Healthcare Pharmaceuticals INC. $22.69 2021
Alnylam Pharmaceuticals INC. $22.16 2019
Horizon Therapeutics Plc $19.35 2020
Scpharmaceuticals INC. $16.38 2024
Medtronic, INC. $14.98 2022
Lemaitre Vascular, INC. $14.84 2019
Portola Pharmaceuticals, LLC $13.69 2019
Medtronic Vascular, INC. $11.88 2019
Kowa Pharmaceuticals America, INC. $11.76 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Bruce Edwin Vannatta

$9,492.10

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $801 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/210007/bruce-edwin-vannatta

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.